MONEY BACK GUARANTEE ON ALL PURCHASES FROM THIS WEBSITE. MONEY BACK GUARANTEE ON ALL PURCHASES FROM THIS WEBSITE.
Home / News / Bioaccumulation of antibiotics
Bioaccumulation of antibiotics

Bioaccumulation of antibiotics

A recent publication in Nature magazine shows how the gut biology can influence how antibiotics are presented to the host. The bottom line is that microbes take up and hold medicines. The effect that this may have is very significant and may explain why some drugs behave so differently from person to person. There is also the question of what may happen when the microbes, for some reason,  release the accumulated medicines into the host.

Below is the abstract.

“Bacteria in the gut can modulate the availability and efficacy of therapeutic drugs. However, the systematic mapping of the interactions between drugs and bacteria has only started recently and the main underlying mechanism proposed is the chemical transformation of drugs by microorganisms (biotransformation).

Here we investigated the depletion of 15 structurally diverse drugs by 25 representative strains of gut bacteria. This revealed 70 bacteria–drug interactions, 29 of which had not to our knowledge been reported before. Over half of the new interactions can be ascribed to bioaccumulation; that is, bacteria storing the drug intracellularly without chemically modifying it, and in most cases without the growth of the bacteria being affected. As a case in point, we studied the molecular basis of bioaccumulation of the widely used antidepressant duloxetine by using click chemistry, thermal proteome profiling and metabolomics. We find that duloxetine binds to several metabolic enzymes and changes the metabolite secretion of the respective bacteria.

When tested in a defined microbial community of accumulators and non-accumulators, duloxetine markedly altered the composition of the community through metabolic cross-feeding. We further validated our findings in an animal model, showing that bioaccumulating bacteria attenuate the behavioural response of Caenorhabditis elegans to duloxetine. Together, our results show that bioaccumulation by gut bacteria may be a common mechanism that alters drug availability and bacterial metabolism, with implications for microbiota composition, pharmacokinetics, side effects and drug responses, probably in an individual manner.”

https://www.nature.com/articles/s41586-021-03891-8?WT.ec_id=NATURE-20210923&utm_source=nature_etoc&utm_medium=email&utm_campaign=20210923&sap-outbound-id=B60DADD1B917731C69D877F42887B595582DF29D